BIONOMICS LTD-ADR (BNOX)

US09063M2052 - ADR

0.2429  -0.01 (-2.88%)

After market: 0.2415 0 (-0.58%)

Fundamental Rating

2

Overall BNOX gets a fundamental rating of 2 out of 10. We evaluated BNOX against 568 industry peers in the Biotechnology industry. BNOX has a bad profitability rating. Also its financial health evaluation is rather negative. BNOX is valued expensive and it does not seem to be growing.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

BNOX had negative earnings in the past year.
BNOX had negative earnings in each of the past 5 years.
In the past 5 years BNOX always reported negative operating cash flow.

1.2 Ratios

BNOX has a worse Return On Assets (-126.05%) than 80.89% of its industry peers.
BNOX has a Return On Equity of -168.68%. This is in the lower half of the industry: BNOX underperforms 65.84% of its industry peers.
Industry RankSector Rank
ROA -126.05%
ROE -168.68%
ROIC N/A
ROA(3y)-41.13%
ROA(5y)-32.67%
ROE(3y)-50.86%
ROE(5y)-54.3%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

BNOX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

BNOX does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for BNOX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -11.22, we must say that BNOX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -11.22, BNOX is not doing good in the industry: 75.93% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.05 indicates that BNOX is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.05, BNOX is not doing good in the industry: 61.59% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -11.22
ROIC/WACCN/A
WACC11.35%

2.3 Liquidity

A Current Ratio of 3.81 indicates that BNOX has no problem at all paying its short term obligations.
The Current ratio of BNOX (3.81) is comparable to the rest of the industry.
A Quick Ratio of 3.81 indicates that BNOX has no problem at all paying its short term obligations.
The Quick ratio of BNOX (3.81) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.81
Quick Ratio 3.81

More info and screens

3

3. Growth

3.1 Past

The earnings per share for BNOX have decreased strongly by -107.33% in the last year.
The Revenue for BNOX has decreased by -87.14% in the past year. This is quite bad
The Revenue for BNOX have been decreasing by -64.58% on average. This is quite bad
EPS 1Y (TTM)-107.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-87.14%
Revenue growth 3Y-10.1%
Revenue growth 5Y-64.58%
Sales Q2Q%N/A

3.2 Future

BNOX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -16.76% yearly.
BNOX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 118.41% yearly.
EPS Next Y33.83%
EPS Next 2Y28.37%
EPS Next 3Y-16.76%
EPS Next 5YN/A
Revenue Next Year-70.47%
Revenue Next 2Y-32.84%
Revenue Next 3Y118.41%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BNOX. In the last year negative earnings were reported.
Also next year BNOX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A cheap valuation may be justified as BNOX's earnings are expected to decrease with -16.76% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.37%
EPS Next 3Y-16.76%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BNOX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIONOMICS LTD-ADR

NASDAQ:BNOX (12/20/2024, 8:00:01 PM)

After market: 0.2415 0 (-0.58%)

0.2429

-0.01 (-2.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-21 2024-02-21
Earnings (Next)N/A N/A
Inst Owners16.93%
Inst Owner Change10.4%
Ins Owners38.23%
Ins Owner Change0%
Market Cap4.74M
Analysts84.44
Price Target6.12 (2419.56%)
Short Float %3.1%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)37.77%
EPS NY rev (3m)37.77%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 145.93
P/FCF N/A
P/OCF N/A
P/B 0.17
P/tB 0.65
EV/EBITDA N/A
EPS(TTM)-4.6
EYN/A
EPS(NY)-0.7
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS1.43
TBVpS0.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -126.05%
ROE -168.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-41.13%
ROA(5y)-32.67%
ROE(3y)-50.86%
ROE(5y)-54.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.81
Quick Ratio 3.81
Altman-Z -11.22
F-ScoreN/A
WACC11.35%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-107.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y33.83%
EPS Next 2Y28.37%
EPS Next 3Y-16.76%
EPS Next 5YN/A
Revenue 1Y (TTM)-87.14%
Revenue growth 3Y-10.1%
Revenue growth 5Y-64.58%
Sales Q2Q%N/A
Revenue Next Year-70.47%
Revenue Next 2Y-32.84%
Revenue Next 3Y118.41%
Revenue Next 5YN/A
EBIT growth 1Y-127.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-3.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.46%
OCF growth 3YN/A
OCF growth 5YN/A